Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company CureVac AG
DescriptionVaccine comprised of modified mRNA components coding for 5 different antigens frequently expressed on NSCLC cells
Molecular Target
Mechanism of ActionVaccine
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPhase I/II
Standard IndicationNon-small cell lung cancer (NSCLC)
Indication DetailsTreat non-small cell lung cancer (NSCLC)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today